Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

EPT Disclosure

22 Mar 2010 10:18

RNS Number : 9299I
Credit Suisse Securities (Eur) Ltd
22 March 2010
 

FORM 38.5 (a)

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITH RECOGNISED INTERMEDIARY STATUS

DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(a) of the Takeover Code)

1. KEY INFORMATION

Name of exempt principal trader

Credit Suisse Securities (Europe) Limited

Company dealt in

Ark Therapeutics Group PLC

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ordinary Shares

Date of dealing

19-Mar-2010

2. DEALINGS (Note 2)

(a) Purchases and sales

Total number of securities purchased

Highest price paid (Note 3)

Lowest price paid (Note 3)

93911

0.1125 (GBP)

0.11 (GBP)

 

Total number of securities sold

Highest price received (Note 3)

Lowest price received (Note 3)

93911

0.1125 (GBP)

0.105 (GBP)

(b) Derivatives transactions (other than options)

Product name, e.g. CFD

Long/short (Note 4)

Number of securities (Note 5)

Price per unit (Note 3)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 3)

(ii) Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 3)

3. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Date of disclosure

22-Mar-2010 09:39:20

Contact name

Eliades,Vassilis D/Carolyn Collins

Telephone number

+44 7810 360119

Name of offeree/offeror with which connected

Ark Therapeutics Group PLC

Nature of connection (Note 6)

ADVISOR

Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMSEIFSEFSSEFD
Date   Source Headline
10th Mar 20101:21 pmRNSEPT Disclosure
10th Mar 201011:52 amRNSEPT Disclosure
10th Mar 20107:00 amRNSFinal Results
9th Mar 20107:00 amRNSResearch Update
8th Mar 20105:34 pmRNSHolding(s) in Company
23rd Feb 20107:00 amRNSResearch Update
19th Feb 20107:00 amRNSRe Agreement
16th Feb 20104:40 pmRNSSecond Price Monitoring Extn
16th Feb 20104:35 pmRNSPrice Monitoring Extension
11th Feb 201011:37 amRNSDirector/PDMR Shareholding
5th Feb 20104:35 pmRNSPrice Monitoring Extension
29th Jan 20103:23 pmRNSTotal Voting Rights
28th Jan 201011:05 amRNSNotice of Results
28th Jan 20107:02 amRNSResearch Update
28th Jan 20107:00 amRNSResearch Update
20th Jan 20103:51 pmRNSEmployee Benefit Trust
5th Jan 20107:00 amRNSArk files for re-examination of Cerepro
22nd Dec 20094:41 pmRNSSecond Price Monitoring Extn
22nd Dec 20094:35 pmRNSPrice Monitoring Extension
18th Dec 200911:56 amRNSEMEA recommendation on Cerepro
15th Dec 20092:29 pmRNSHolding(s) in Company
3rd Dec 20092:41 pmRNSBlocklisting Interim Review
3rd Dec 20092:35 pmRNSHolding(s) in Company
24th Nov 20094:04 pmRNSHolding(s) in Company
11th Nov 20097:00 amRNSInterim Management Statement
14th Oct 20097:00 amRNSResearch Update
2nd Oct 200911:04 amRNSHolding(s) in Company
30th Sep 200910:51 amRNSHolding(s) in Company
29th Sep 20094:32 pmRNSHolding(s) in Company
4th Sep 20097:00 amRNSResearch Update
1st Sep 200912:08 pmRNSDirector/PDMR Shareholding
26th Aug 20097:00 amRNSResearch Update
26th Aug 20097:00 amRNSHalf Yearly Report
13th Jul 20097:00 amRNSArk launches Kerraglove woundcare device
1st Jul 20097:00 amRNSRe Agreement
26th Jun 20092:15 pmRNSHolding(s) in Company
24th Jun 20097:00 amRNSManufacturing Update
17th Jun 20097:00 amRNSRe Agreement
3rd Jun 200911:47 amRNSBlocklisting Interim Review
21st May 20097:00 amRNSTrinam Phase III Study Enrols First Patient
18th May 20097:00 amRNSInterim Management Statement
15th May 20097:00 amRNSCerepro Named Patient Supply approved in Finland
13th May 20094:41 pmRNSSecond Price Monitoring Extn
13th May 20094:35 pmRNSPrice Monitoring Extension
12th May 20097:00 amRNSDirector/PDMR Shareholding
6th May 20094:40 pmRNSSecond Price Monitoring Extn
6th May 20094:35 pmRNSPrice Monitoring Extension
5th May 20097:00 amRNSTrinam(R) Awarded Fast Track Status by FDA
30th Apr 20094:01 pmRNSTotal Voting Rights
30th Apr 200912:00 pmRNSPrestigious European Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.